BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37938771)

  • 21. Identification of a Promiscuous Epitope Peptide Derived From HSP70.
    Matsui H; Hazama S; Tamada K; Udaka K; Irie A; Nishimura Y; Miyakawa T; Doi S; Nakajima M; Kanekiyo S; Tokumitsu Y; Shindo Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Ueno T; Nagano H
    J Immunother; 2019 Sep; 42(7):244-250. PubMed ID: 31398179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia.
    Xie G; Ivica NA; Jia B; Li Y; Dong H; Liang Y; Brown D; Romee R; Chen J
    Nat Biomed Eng; 2021 May; 5(5):399-413. PubMed ID: 33046866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell Receptors Engineered
    Sharma P; Harris DT; Stone JD; Kranz DM
    Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles.
    Celis E; Fikes J; Wentworth P; Sidney J; Southwood S; Maewal A; Del Guercio MF; Sette A; Livingston B
    Mol Immunol; 1994 Dec; 31(18):1423-30. PubMed ID: 7823968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
    Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
    Front Immunol; 2020; 11():576603. PubMed ID: 33329543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
    Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
    Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
    Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
    Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.
    Doubrovina E; Carpenter T; Pankov D; Selvakumar A; Hasan A; O'Reilly RJ
    Blood; 2012 Aug; 120(8):1633-46. PubMed ID: 22623625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse.
    Charneau J; Suzuki T; Shimomura M; Fujinami N; Mishima Y; Hiranuka K; Watanabe N; Yamada T; Nakamura N; Nakatsura T
    Cancer Sci; 2022 Apr; 113(4):1113-1124. PubMed ID: 35122353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4.
    Jia ZC; Ni B; Huang ZM; Tian Y; Tang J; Wang JX; Fu XL; Wu YZ
    Clin Dev Immunol; 2010; 2010():567594. PubMed ID: 21350607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.
    Escobar P; Yu Z; Terskikh A; Holmes N; Corradin G; Mach JP; Healy F
    Clin Exp Immunol; 1999 May; 116(2):214-9. PubMed ID: 10337009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
    Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
    Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides.
    Puig M; Ananthula S; Venna R; Kumar Polumuri S; Mattson E; Walker LM; Cardone M; Takahashi M; Su S; Boyd LF; Natarajan K; Abdoulaeva G; Wu WW; Roderiquez G; Hildebrand WH; Beaucage SL; Li Z; Margulies DH; Norcross MA
    Front Immunol; 2020; 11():629399. PubMed ID: 33633747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
    Bauer M; Wagner H; Lipford GB
    Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.